Magic™ Anti-Catalase (Internal)(phospho Y386) polyclonal antibody

Herein, the quercetin-human serum albumin (HSA) nano-complex was formulated and its capability to decrease H2O2-stimulated cytotoxicity against spinal cord neurons as a model of preventive care study was investigated by cellular assays. Quercetin molecules were first encapsu-lated into HSA as a shell and the loading efficiency along with drug release and different properties of formulated nano-complex were determined using TEM, SEM, and DLS approaches. Afterwards using CD spectroscopic method and theoritical analysis, the structural changes and binding redisues of HSA after interaction with quercetin were investigated, respectively. Finally, the antioxidant activity of quercetin-HSA nano-complex against H2O2 (200 mu M)-stimulated cytotoxicity in spinal cord neurons was explored by MTT, SOD and CAT activity, and morphological changes assays. It was shown that the fabrication of quercetin-HSA nano-complex resulted in the improved bioavailability of quercetin with an entrapment efficiency of 68.99% and percent yield of 53.19%. Also, molecular docking study showed that quercetin molecules spontaneously bind to HSA through hydrogen bonds and van der Waals interactions. Furthermore, CD data indicated that the quercetin did not change the secondary structure of HSA. Finally, cellular assays displayed that the pre-treatments of spinal cord neurons with quercetin-HSA nano-complex attenuated the H2O2-triggerd neuron mortality through a significant increase in the activity of SOD and CAT and prevention of morphological changes. In conclusion, it may be suggested that the formulation of quercetin into nano-complex can improve its medical properties and this new developed drug formulation may hold a great promise in the advancement of antioxidant compounds in preventive care services. (C) 2020 The Author(s). Published by Elsevier B.V. on behalf of King Saud University.

Background Arterial thromboembolism is a sequela of hypertrophic cardiomyopathy (HCM) in cats related to left atrial (LA) enlargement and dysfunction. Hypothesis Pimobendan improves LA transport function in cats. Animals Twenty-two client-owned cats with HCM and 11 healthy cats. Methods Prospective, double-blind, randomized, placebo-controlled clinical cohort study. Cats were randomized to receive either pimobendan (0.25 mg/kg PO q12h) or placebo for 4 to 7 days. Nineteen echocardiographic variables of LA size and function were evaluated. Statistical comparisons included t tests, analysis of variance, and multivariable analyses. Results Peak velocity of left auricular appendage flow (LAapp peak; mean +/- SD, 0.85 +/- 0.20 vs 0.71 +/- 0.22 m/s; P = .01), maximum LA volume (P = .03), LA total emptying volume (P = .03), peak velocity of late diastolic transmitral flow (A peak velocity; 0.77 +/- 0.12 vs 0.62 +/- 0.17 m/s; P = .05), and A velocity time integral (A VTI; 3.05 +/- 0.69 vs 3.37 +/- 0.49; P = .05) were increased after pimobendan. Mean change after pimobendan was larger in cats with HCM compared to healthy cats for LA fractional shortening (2.1% vs -2.1%; P = .05), A VTI (0.58 vs 0.01 cm; P = .01), LAapp peak (0.20 vs 0.02 m/s; P = .02), LA kinetic energy (3.51 vs -0.10 kdynes-cm; P = .05), and LA ejection force (1.93 vs -0.07 kdynes; P = .01) in the multivariable model. The stronger effect of pimobendan in cats with HCM was independent of LA size. Conclusions and Clinical Importance We identified positive, albeit minor, effects of pimobendan on LA function in cats with HCM. Whether or not treatment with pimobendan decreases the risk of cardiogenic embolism deserves further study.